By Sudeshna Ray
Edited by Neha Mehrotra

Main Facts

In a move that caught India’s healthcare investment landscape entirely off guard, Coimbatore-headquartered eye-care chain The Eye Foundation made a definitive break from industry norms. Exactly a year ago, the 40-year-old regional specialty provider raised external equity for the first time in its history—bypassing healthcare-exclusive private equity (PE) giants in favor of Verlinvest, a venture capital fund historically recognized for backing consumer brands, direct-to-consumer (D2C) retail, and fast-moving consumer goods (FMCG) like Epigamia, Wakefit, and Purplle.

The transaction, finalized in October 2025, saw Verlinvest inject Rs 650 crore in exchange for a 20% stake in the eye-care chain. This valuation places The Eye Foundation on par with prominent competitor ASG Eye Hospital and positions it comfortably ahead of the implied valuation metrics seen in Dr. Agarwal’s latest fundraise cycles.

While traditional healthcare providers in India—which have collectively vacuumed up more than $15.5 billion over the past five years, with roughly 60% flowing directly into hospital networks—rely on healthcare-dedicated PE syndicates such as Temasek, Blackstone, TPG, and KKR, The Eye Foundation chose a fundamentally different trajectory. Rather than chasing aggressive, inorganic acquisition sprees funded by short-term capital, the company opted for strategic longevity, stable financial performance, and eye-popping EBITDA margins hovering around 35%—a financial feat that continues to baffle industry analysts operating under stringent regulatory clouds.

Chronology of Events

To understand the weight of The Eye Foundation’s pivot, it is essential to trace the historical progression of its funding journey and the parallel expansion patterns of its peer group across India:

• Foundation and Organic Scaling (Decades 1–3): Established in Coimbatore over 40 years ago, The Eye Foundation built its reputation slowly through clinical excellence, organic expansion, and disciplined balance-sheet management, carefully avoiding institutional equity dilution.
• The Private Equity Boom (2020–2023): India’s broader healthcare sector witnessed a massive liquidity influx. Heavyweights like TPG and Temasek pumped a combined Rs 1,050 crore in 2022 and an additional Rs 640 crore in 2023 into networks like Dr. Agarwal’s Eye Hospital. The vast majority of these funds were immediately deployed toward rapid acquisitions.
• The Accumulation Phase (2023–2026): Driven by their PE backers, chains like Dr. Agarwal’s embarked on an aggressive buying spree. Over a three-year period leading to FY26, Dr. Agarwal’s poured Rs 1,215 crore into acquisitions, despite generating only about Rs 315 crore in free cash flow, highlighting a high-burn, high-growth consolidation model.
• The Unconventional Pivot (October 2025): Facing a growing roster of interested suitors drawn to its immaculate balance sheet, The Eye Foundation officially broke its bootstrapped model. It rejected traditional healthcare funds and accepted Rs 650 crore from consumer-focused Verlinvest for a 20% equity stake.
• Financial Trajectory (FY24–FY27 Projected): The company’s financial health continued its steady ascent. Top-line revenues grew from Rs 278 crore in FY24 to Rs 330 crore in FY25, and Rs 409 crore in FY26, with projections tracking toward a remarkable 35% year-on-year jump to touch Rs 550 crore in FY27.

Supporting Data and Financial Performance

A closer look at the financial metrics reveals stark structural differences between The Eye Foundation and its PE-backed counterparts. In a sector where compliance costs, high-end equipment imports, and aggressive real estate leasing typically compress margins, The Eye Foundation’s performance stands out as an outlier.

Financial Comparison Table

Industry analysts interviewed by business publication The Ken noted that maintaining EBITDA margins above 30% in modern healthcare is a rarity, particularly given the tightening regulatory frameworks governing clinical pricing, medical device standards, and compliance across India. For comparison, Dr. Agarwal’s and ASG recorded EBITDA margins of approximately 29% (FY26) and 22.6% (FY25), respectively—figures that, while respectable, reflect the heavy operational drag and integration costs associated with aggressive multi-city acquisitions.

Official Responses and Strategic Rationale

The decision to invite a consumer-focused venture capital firm into a clinical healthcare setup generated substantial debate within India’s corporate finance circles. However, the leadership at The Eye Foundation remains firm on the strategic wisdom of the partnership.

D. Ramamurthy, Founder and CEO of The Eye Foundation, candidly acknowledged that selecting an FMCG-oriented fund was “unusual for the sector.” However, he underscored that the choice was guided by a deliberate aversion to short-term exit timelines typical of standard private equity operators.

“We did not want a fly-by-night operator—somebody with a definite timeline who wants to exit in five years,” Ramamurthy stated, explaining the foundational philosophy that kept the chain independent for four decades.

Ramamurthy noted that the company had no shortage of suitors vying for a piece of its equity story, courtesy of its pristine balance sheet and predictable cash flows. By engaging with Verlinvest, the chain secured not only a favorable valuation—pegged competitively alongside ASG and scaling past Dr. Agarwal’s latest metrics—but also an investor aligned with long-term brand building, customer experience, and retail-like scaling methodologies rather than rapid, debt-fueled rollup strategies.

Broader Implications for India’s Healthcare Sector

The partnership between The Eye Foundation and Verlinvest signals a potential paradigm shift in how specialized healthcare services are funded and scaled in emerging markets like India.

1. Re-evaluating the Private Equity Playbook

For over a decade, the dominant narrative in Indian healthcare investments has centered on aggressive consolidation. PE funds routinely pump hundreds of millions of dollars into regional hospital chains, pushing them to acquire smaller clinics rapidly to build national footprints before a liquidity event or public listing. However, as demonstrated by Dr. Agarwal’s deployment of Rs 1,215 crore on acquisitions against just Rs 315 crore in free cash flow, this model carries immense capital intensity and margin pressure. The Eye Foundation proves that sustainable, organic-led growth paired with high margins can command top-tier valuations without sacrificing operational independence.

2. The Consumerization of Healthcare Delivery

Verlinvest’s entry into eye care highlights a broader trend: modern healthcare consumers increasingly evaluate specialty clinics through a retail and customer-experience lens. Consumer-focused funds bring invaluable expertise in brand loyalty, digital patient acquisition, supply chain optimization, and standardized service delivery—skills traditionally underemphasized by clinical operators. By blending medical rigor with FMCG-style brand scaling, chains can build resilient moats that transcend simple geographic expansion.

3. Regulatory Resilience and Margin Protection

With regulatory scrutiny over healthcare pricing, medical ethics, and corporate governance intensifying across India, high-margin, disciplined operators are better positioned to weather macroeconomic shocks. While acquisition-heavy networks struggle with integration friction and debt servicing, lean operators maintaining 35% EBITDA margins retain the financial agility to invest organically in cutting-edge diagnostic technology and talent acquisition.

As India’s healthcare landscape continues to mature, The Eye Foundation’s unconventional alignment with an FMCG fund may well serve as a blueprint for specialized medical providers seeking patient capital, strategic clarity, and long-term enterprise value over rushed financial exits.